US2004180910A1PendingUtilityA1
Heterocycle carboxamides as antiviral agents
Priority: Jul 12, 2000Filed: Mar 29, 2004Published: Sep 16, 2004
Est. expiryJul 12, 2020(expired)· nominal 20-yr term from priority
A61P 31/22A61P 31/20A61P 31/12A61P 43/00C07D 217/26C07D 405/06C07D 217/14C07D 471/04
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of formula I,
wherein,
X is Cl, Br, F, CN or NO 2 ;
G is (a) C 1-7 alkyl which partially unsaturated and is substituted by hydroxy, or
(b) C 1-4 alkyl substituted by NR 1 R 2 or 4-tetrahydropyran;
R 1 is C 2-7 alkyl substituted by hydroxy, C 1-4 alkoxy, aryl, or heteroaryl;
R 2 is hydrogen or C 1-7 alkyl;
or R 1 and R 2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C 1-7 alkyl;
W is a heterocycle of formula W1, W3, or W4;
A is CR 4 or nitrogen;
B is CR 5 or nitrogen;
C is CR 6 or nitrogen;
E and F are such that (a) one is oxygen and the other is C(═O); or
(b) E is C(═O) and F is NR 7 ;
J and K are such that (a) J is nitrogen and K is CR 8 ; or
(b) J is CR 6 and K is nitrogen;
with the provisos that when W is of formula W3 and J is nitrogen, then at least one of
A and B is nitrogen;
R 4 is H, halogen, or C 1-4 alkyl optionally substituted by one to three halogens;
R 5 is (a) H,
(b) halo,
(c) OR 12 ,
(d) SR 12 ,
(e) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(f) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(g) (C═O)R 9 ,
(h) S(O) m R 9 ,
(i) (C═O)OR 2 ,
(j) NHSO 2 R 9 ,
(k) nitro, or
(l) cyano;
R 6 is (a) H,
(b) halo,
(c) aryl,
(d) het,
(e) OR 12 ,
(f) SR 12 ,
(g) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , aryl, halo, C 3-8 cycloalkyl optionally substituted by OR 12 , or het attached through a carbon atom,
(h) NR 10 R 11 ,
(i) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(j) (C═O)R 9 ,
(k) S(O) m R 9 ,
(l) (C═O)OR 2 ,
(m) NHSO 2 R 9 ,
(n) nitro, or
(o) cyano;
R 7 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(d) aryl, or
(e) het;
R 8 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) OR 12 , or
(d) SR 12 ;
R 9 is (a) C 1-7 alkyl,
(b) NR 10 R 11 ,
(c) aryl, or
(d) het, wherein said het is bound through a carbon atom;
R 10 and R 11 are independently
(a) H,
(b) aryl,
(c) C 1-7 alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR 2 R 2 , CO 2 R 2 , het, aryl, cyano, or halo,
(d) C 2-7 alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR 2 R 2 , OR 2 , or SR 2 ,
(e) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 , or
(f) R 10 and R 11 together with the nitrogen to which they are attached form a het;
R 12 is (a) H,
(b) aryl,
(c) het
(d) C 1-7 alkyl optionally substituted by aryl, het, or halogen,
(e) C 2-7 alkyl substituted by OR 2 , SR 2 , or NR 2 R 2 , or
(f) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 ;
each m is independently 1 or 2;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR 2 R 2 , CO 2 R 2 , CF 3 , C 1-6 alkoxy, and C 1-6 alkyl which maybe further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO 2 R 2 , CF 3 , C 1-6 alkoxy, oxo, oxime, and C 1-6 alkyl which may be further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
halo or halogen is F, Cl, Br, I;
1 represents the point of attachment between W and G;
2 represents the point of attachment between W and the carbonyl group of Formula (I);
and a pharmaceutically acceptable salt thereof;
2 . A compound of claim 1 wherein W is of the formula W1.
3 . A compound of claim 2 wherein W is of the formula W1.1.
4 . A compound of claim 2 wherein W is of the formula W1.2.
5 . A compound of claim 2 wherein W is of the formula W1.3.
6 . A compound of claim 2 wherein W is of the formula W1.4.
7 . A compound of claim 2 wherein W is of the formula W1.5.
8 . A compound of claim 2 wherein W is of the formula W1.6.
9 . A compound of claim 2 wherein W is of the formula W1.7.
10 . A compound of claim 2 wherein W is of the formula W1.8.
11 . A compound of claim 2 wherein W is of the formula W1.9.
12 . A compound of claim 2 wherein W is of the formula W1.10.
13 . A compound of claim 2 wherein W is of the formula W1.11.
14 . A compound of claim 2 wherein W is of the formula W1.12.
15 . A compound of claim 2 wherein W is of the formula W1.13.
16 . A compound of claim 2 wherein W is of the formula W1.14.
17 . A compound of claim 2 wherein W is of the formula W1.15.
18 . A compound of claim 2 wherein W is of the formula W1.16.
19 . A compound of claim 2 wherein W is of the formula W1.17.
20 . A compound of claim 2 wherein W is of the formula W1.18.
21 . A compound of claim 2 wherein W is of the formula W1.19.
22 . A compound of claim 2 wherein W is of the formula W1.20.
23 . A compound of claim 2 wherein W is of the formula W1.21.
24 . A compound of claim 2 wherein W is of the formula W1.22.
25 . A compound of claim 2 wherein W is of the formula W1.23.
26 . A compound of claim 1 wherein W is of the formula W3.
27 . A compound of claim 26 wherein W is of the formula W3.1.
28 . A compound of claim 26 wherein W is of the formula W3.2.
29 . A compound of claim 26 wherein W is of the formula W3.3.
30 . A compound of claim 26 wherein W is of the formula W3.4.
31 . A compound of claim 26 wherein W is of the formula W3.5.
32 . A compound of claim 26 wherein W is of the formula W3.6.
33 . A compound of claim 26 wherein W is of the formula W3.7.
34 . A compound of claim 26 wherein W is of the formula W3.8.
35 . A compound of claim 26 wherein W is of the formula W3.9.
36 . A compound of claim 26 wherein W is of the formula W3.10.
37 . A compound of claim 26 wherein W is of the formula W3.11.
38 . A compound of claim 26 wherein W is of the formula W3.12.
39 . A compound of claim 26 wherein W is of the formula W3.13.
40 . A compound of claim 26 wherein W is of the formula W3.14.
41 . A compound of claim 1 wherein W is of-the formula W4.
42 . The compound according to claim 1 , wherein X is Cl.
43 . The compound according to claim 1 wherein G is 4-morpholinylmethyl.
44 . The compound according to claim 1 wherein G is 3-hydroxy-1-propynyl.
45 . The compound according to claim 1 wherein G is tetrahydro-2H-pyran-4-ylmethyl.
46 . The compound according to claim 1 which is
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-2-oxo-2H-pyrano[2,3-c]pyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1H-isochromene-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-1-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1H-isochromene-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1H-isochromene-3-carboxamide;
N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-8-oxo-7,8-dihydro[1,7]-naphthyridine-6-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]-naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,5]naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2H-pyran-4-ylmethyl)[1,5]-naphthyridine-3-carboxamide;
N-(4-chlorobenzyl)-8-hydroxy-2-(3-hydroxy-1-propynyl)pyrido[3,2-d]pyrimidine-7-carboxamide;
N-(4-chlorobenzyl)-8-hydroxy-2-(4-morpholinylmethyl)pyrido[3,2-d]pyrimidine-7-carboxamide;
N-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)[1,7]naphthyridine-6-carboxamide;
N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide;
N-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2H-pyran-4-ylmethyl)[1,7]-naphthyridine-6-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-isoquinolinecarboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-3-isoquinolinecarboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-isoquinoline-carboxamide; or
a pharmaceutically acceptable salt thereof.
47 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
48 . A method of treating or preventing a viral infection, comprising administering to a mammal in need of such treatment, a compound of formula (I),
wherein,
X is Cl, Br, F, CN or NO 2 ;
G is (a) C 3-7 alkyl which is partially unsaturated and is substituted by hydroxy,
(b) C 1-7 alkyl which is fully saturated and is substituted by hydroxy, or
(c) C 1-4 alkyl substituted by NR 1 R 2 or 4-tetrahydropyran;
R 1 is C 2-7 alkyl substituted by hydroxy, C 1-4 alkoxy, aryl, or heteroaryl;
R 2 is hydrogen or C 1-7 alkyl;
or R 1 and R 2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C 1-7 alkyl;
W is a heterocycle of formula W1, W3, or W4;
A is CR 4 or nitrogen;
B is CR 5 or nitrogen;
C is CR 6 or nitrogen;
E and F are such that (a) one is oxygen and the other is C(═O); or
(b) E is C(═O) and F is NR 7 ;
J and K are such that (a) J is nitrogen and K is CR 8 ; or
(b) J is CR 6 and K is nitrogen;
with the provisos that when W is of formula W3 and J is nitrogen, then at least one of
A and B is nitrogen;
R 4 is H, halogen, or C 1-4 alkyl optionally substituted by one to three halogens;
R 5 is (a) H,
(b) halo,
(c) OR 12 ,
(d) SR 12 ,
(e) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(f) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(g) (C═O)R 9 ,
(h) S(O) m R 9 ,
(i) (C═O)OR 2 ,
(j) NHSO 2 R 9 ,
(k) nitro, or
(l) cyano;
R 6 is (a) H,
(b) halo,
(c) aryl,
(d) het,
(e) OR 12 ,
(f) SR 12 ,
(g) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , aryl, halo, C 3-8 cycloalkyl optionally substituted by OR 12 , or het attached through a carbon atom,
(h) NR 10 R 11 ,
(i) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(j) (C═O)R 9 ,
(k) S(O) m R 9 ,
(l) (C═O)OR 2 ,
(m) NHSO 2 R 9 ,
(n) nitro, or
(o) cyano;
R 7 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(d) aryl, or
(e) het;
R 8 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) OR 12 , or
(d) SR 12 ;
R 9 is (a) C 1-7 alkyl,
(b) NR 10 R 11 ,
(c) aryl, or
(d) het, wherein said het is bound through a carbon atom;
R 10 and R 11 are independently
(a) H,
(b) aryl,
(c) C 1-7 alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR 2 R 2 , CO 2 R 2 , het, aryl, cyano, or halo,
(d) C 2-7 alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR 2 R 2 , OR 2 , or SR 2 ,
(e) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 , or
(f) R 10 and R 11 together with the nitrogen to which they are attached form a het; R 12 is (a) H,
(b) aryl,
(c) het
(d) C 1-7 alkyl optionally substituted by aryl, het, or halogen,
(e) C 2-7 alkyl substituted by OR 2 , SR 2 , or NR 2 R 2 , or
(f) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 ;
each m is independently 1 or 2;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR 2 R 2 , CO 2 R 2 , CF 3 , C 1-6 alkoxy, and C 1-6 alkyl which maybe further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO 2 R 2 , CF 3 , C 1-6 alkoxy, oxo, oxime, and C 1-6 alkyl which may be further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
halo or halogen is F, Cl, Br, I;
1 represents the point of attachment between W and G;
2 represents the point of attachment between W and the carbonyl group of Formula (I);
and a pharmaceutically acceptable salt thereof;
49 . The method according to claim 48 wherein said viral infection is a herpes virus infection.
50 . The method according to claim 48 wherein said mammal is a human.
51 . The method according to claim 48 wherein said mammal is a food animal or companion animal.
52 . The method according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type, 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.
53 . The method according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.
54 . The method according to claim 48 wherein the amount administered is from about 0.1 to about 300 mg/kg of body weight.
55 . The method according to claim 48 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.
56 . The method according to claim 48 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.
57 . A method for inhibiting a viral DNA polymerase, comprising contacting the polymerase with an effective inhibitory amount of a compound of the formula (I)
wherein,
X is Cl, Br, F, CN or NO 2 ;
G is (a) C 3-7 alkyl which is partially unsaturated and is substituted by hydroxy,
(b) C 1-7 alkyl which is fully saturated and is substituted by hydroxy, or
(c) C 1-4 alkyl substituted by NR 1 R 2 or 4-tetrahydropyran;
R 1 is C 2-7 alkyl substituted by hydroxy, C 1-4 alkoxy, aryl, or heteroaryl;
R 2 is hydrogen or C 1-7 alkyl;
or R 1 and R 2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C 1-7 alkyl;
W is a heterocycle of formula W1, W3, or W4;
A is CR 4 or nitrogen;
B is CR 5 or nitrogen;
C is CR 6 or nitrogen;
E and F are such that (a) one is oxygen and the other is C(═O); or
(b) E is C(═O) and F is NR 7 ;
J and K are such that (a) J is nitrogen and K is CR 8 ; or
(b) J is CR 6 and K is nitrogen;
with the provisos that when W is of formula W3 and J is nitrogen, then at least one of
A and B is nitrogen;
R 4 is H, halogen, or C 1-4 alkyl optionally substituted by one to three halogens;
R 5 is (a) H,
(b) halo,
(c) OR 12 ,
(d) SR 12 ,
(e) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(f) C 3 -cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(g) (C═O)R 9 ,
(h) S(O) m R 9 ,
(i) (C═O)OR 9 ,
(j) NHSO 2 R 9 ,
(k) nitro, or
(l) cyano;
R 6 is (a) H,
(b) halo,
(c) aryl,
(d) het,
(e) OR 12 ,
(f) SR 12 ,
(g) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , aryl, halo, C 3-8 cycloalkyl optionally substituted by OR 12 , or het attached through a carbon atom,
(h) NR 10 R 11 ,
(i) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(j) (C═O)R 9 ,
(k) S(O) m R 9 ,
(l) (C═O)OR 9 ,
(m) NHSO 2 R 9 ,
(n) nitro, or
(o) cyano;
R 7 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 12 , SR 12 , or NR 10 R 11 ,
(d) aryl, or
(e) het;
R 8 is (a) H,
(b) C 1-7 alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR 12 , SR 12 , NR 10 R 11 , or halo,
(c) OR 12 , or
(d) SR 12 ;
R 9 is (a) C 1-7 alkyl,
(b) NR 10 R 11 ,
(c) aryl, or
(d) het, wherein said het is bound through a carbon atom;
R 10 and R 11 are independently
(a) H,
(b) aryl,
(c) C 1-7 alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR 2 R 2 , CO 2 R 2 , het, aryl, cyano, or halo,
(d) C 2-7 alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR 2 R 2 , OR 2 , or SR 2 ,
(e) C 3 -cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 , or
(f) R 10 and R 11 together with the nitrogen to which they are attached form a het;
R 2 is (a) H,
(b) aryl,
(c) het
(d) C 1-7 alkyl optionally substituted by aryl, het, or halogen,
(e) C 2-7 alkyl substituted by OR 2 , SR 2 , or NR 2 R 2 , or
(f) C 3-8 cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR 2 , SR 2 , or NR 2 R 2 ;
each m is independently 1 or 2;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR 2 R 2 , CO 2 R 2 , CF 3 , C 1-6 alkoxy, and C 1-6 alkyl which maybe further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO 2 R 2 , CF 3 , C 1-6 alkoxy, oxo, oxime, and C 1-6 alkyl which may be further substituted by one to three SR 2 , NR 2 R 2 , OR 2 , or CO 2 R 2 groups;
halo or halogen is F, Cl, Br, I;
1 represents the point of attachment between W and G;
2 represents the point of attachment between W and the carbonyl group of Formula (I);
and a pharmaceutically acceptable salt thereof;
58 . The method of claim 57 wherein the polymerase and the compound are contacted in vitro.
59 . The method of claim 57 wherein the polymerase and the compound are contacted in vivo.Join the waitlist — get patent alerts
Track US2004180910A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.